AstraZeneca Cuts 3,000 Manufacturing Jobs, Pares Down Therapeutic Areas
Executive Summary
AstraZeneca's focus on improving manufacturing efficiencies, on the heels of similar moves by Merck and Pfizer, may signal that manufacturing is the next target for industry cost-cutting initiatives
You may also be interested in...
Pipeline Dreams: GSK’s Witty Outlines Plans To Lower Phase III Attrition
As Andrew Witty takes the helm at GlaxoSmithKline, he has set his sights on tackling one of the industry's biggest challenges: reducing attrition in the late-stage pipeline
Pipeline Dreams: GSK’s Witty Outlines Plans To Lower Phase III Attrition
As Andrew Witty takes the helm at GlaxoSmithKline, he has set his sights on tackling one of the industry's biggest challenges: reducing attrition in the late-stage pipeline
AstraZeneca Aims To Grow Seroquel XR With Added Indications, Not Switches
AstraZeneca is looking to establish Seroquel XR, the sustained-release line extension of its atypical antipsychotic quetiapine, by adding unique indications rather than pushing to switch patients from immediate-release Seroquel